Key Drivers
- Margin Expansion
- Debt Reduction
- Negative Equity
AIAI Summary
Ironwood's LINZESS pricing reset has restored high-margin cash generation and creates a credible deleveraging opportunity, shifting the thesis from imminent distress to a prove-it cash-flow recovery; investors should require sustained guidance delivery and debt reduction, however, because pricing-led, single-product dependence ahead of 2029–2030 patent expiry remains the decisive risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Debt Reduction
- •Negative Equity
IRWD's profitability, liquidity, and valuation improved sharply, but substantial net debt and persistent negative equity warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Recent rebound
- •Key resistance
- •Volatile range
IRWD is modestly bullish over the last month, rebounding to $4.36 with RSI near 59, but needs a break above $4.39–$4.41 while holding $4.05–$4.08 support.
Sharp swings during the period signal elevated volatility
Sentiment & News
Key News Insights:
- •Raised LINZESS Guidance
- •Positive Phase 3
- •Patent Expiry Risk
Ironwood's raised LINZESS guidance and positive apraglutide Phase 3 results strengthen near-term momentum, though future growth depends on pipeline execution ahead of patent expiries.
The news is broadly positive for IRWD, but sustained valuation upside hinges on successful apraglutide commercialization
Similar Companies in Healthcare
Other companies in the same sector with AI ratings